Abiopharma

🔍 Kaye Edward M. MD (Executive)

Company: Stoke Therapeutics, Inc. (STOK)

Report Date: 2025-12-03

Detailed Transactions and Holdings:

• Acquired 26,250 shares of Common Stock (Direct)
  Date: 2025-12-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 77,555.00 | transaction_form_type: 4
• Sold 5,222 shares of Common Stock at $30.7635 per share (Direct)
  Date: 2025-12-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 72,333.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,231 shares of Common Stock at $31.3164 per share (Direct)
  Date: 2025-12-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 71,102.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 6,367 shares of Common Stock at $31.3304 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,735.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 1,681 shares of Common Stock at $31.1468 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 63,054.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 500 shares of Common Stock at $31.846 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,554.00 | transaction_form_type: 4 | Footnotes: F5, F7
• Sold 26,250 shares of Performance Stock Units (Derivative)
  Date: 2025-12-03 | Code: M | Expires: 2025-12-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F8, F9

Footnotes:

• F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
• F5: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.
• F8: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• F9: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.